🦠 The Regulatory and Pricing Challenge: Generic Erosion vs. Premium Curative Therapies
The commercial dynamics of the Hepatitis B Treatment Market are characterized by a significant tension between the low-cost volume of generic chronic care and the anticipated high price of novel curative regimens. The standard-of-care market for Nucleos(t)ide Analogs, such as Tenofovir and Entecavir, has undergone substantial generic erosion in major markets. This competition has driven down...
0 Comments 0 Shares 39 Views 0 Reviews